Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.
Checked against the public recordLast updated May 11, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Boston Medical Center
- Interventions being studied
- Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: hypofractionated radiation therapy; Radiation: stereotactic radiosurgery
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer * Stage I or II disease (T1-3, N0, M0) * T2 or T3 tumor ≤ 5 cm * No T3 tumors involving the central chest or mediastinum (only chest wall involvement allowed) * Tumor deemed technically resectable, in the opinion of an experienced thoracic surgeon, AND patient deemed "medically inoperable" * Patients with fluorodeoxyglucose (FDG)-avidity in mediastinal lymph nodes are eligible provided they are able to undergo mediastinoscopy to confirm N0 status PATIENT CHARACTERISTICS: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Not pregnant or nursing * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment Exclusion Criteria: * No history of contrast allergy * No psychological issues that would preclude the completion of study treatment PRIOR CONCURRENT THERAPY: * No prior radiotherapy or chemotherapy * No suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e., hilar or mediastinal nodes that are either fludeoxyglucose F 18 \[FDG\]-avid or measure \> 1 cm in short axis diameter on CT scan) * No tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm in all directions around the proximal bronchial tree (carina, right and left main stem bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Boston University Cancer Research CenterBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 11, 2018. Always confirm current availability with the study team.